A study published in the Journal of the National Comprehensive Cancer Network adds important knowledge about how immunotherapy-related adverse events can impact more than one organ in a single patient.
City of Hope scientists have combined two immunotherapies—an oncolytic virus and chimeric antigen receptor CAR T-cell therapy—to target and eradicate solid tumors that are otherwise difficult to treat with CAR T therapy alone, according to a study in Science Translational Medicine.
Data from the pivotal GEOMETRY mono-1 phase II study show treatment with Tabrecta (capmatinib, formerly INC280) resulted in positive overall response rates among adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to skipping of MET exon 14. Positive duration of response was also observed.
Mays Cancer Center has received a renewal of its NCI-designation for the next five years.
Justin Leung, of University of Arkansas for Medical Sciences, has received a $1.9 million grant from the National Institute of General Medical Studies to advance his research of DNA damage response in cancer and genetic disorders.
Surupa Sen Gupta has joined Maryland Oncology Hematology as a breast surgeon, with expertise in breast cancer biology, genetics, and advanced oncoplastic surgical techniques and breast preservation procedures.
I was disappointed to see that you reported on the results of the IMpassion 131 trial, without context. [The Cancer Letter, Sept. 4, 2020]
On behalf of the ECOG-ACRIN Cancer Research Group
NCI's publicly announced move to create an ad hoc working group that would review the feasibility and viability of the TMIST trial threatens to undercut this trial, said Mitchell Schnall, co-chair of ECOG-ACRIN Cancer Research Group, the group conducting the study.
The National Cancer Institute approved the following clinical research studies last month.
